CGT Catapult Morning Tips - Industry 4.0: the future of ATMP manufacturing
Grab a coffee and start your day with the CGT Catapult Morning Tips webinar series exploring the latest challenges and solutions in ATMP development and manufacturing. Featuring insights and discussion with experts in the cell and gene therapy field, in this series you will learn how researchers and industry are working collaboratively to address common challenges and discover innovative technologies that are defining the future of our sector.
In this first series, Embracing Industry 4.0, topics covered during the webinars include:
- Industry 4.0: the future of ATMP manufacturing
- Big Data’s role in evolving ATMP manufacturing
- Improving reliability with process analytical technologies
- Using automation to overcome analysis bottlenecks
Each 20-minute talk will be followed by a 10-minute Q&A session with the speakers.
We look forward to seeing you there!
Dr Marc Olivier Baradez
Head of Data Sciences
Cell and Gene Therapy Catapult
Marc-Olivier is Head of Data Sciences at the Cell and Gene Therapy Catapult. He has over 14 years of industrial experience in the implementation of analytical strategies for the characterization of cell and gene therapies. He leads the Catapult’s core Data Intelligence program, focusing on high-throughput data generation, data management and analysis, innovative methodologies for Quality-by-Design and in-process controls in the context of Intelligent Manufacturing, across a wide portfolio of cell and gene therapy products and processes. Marc-Olivier’s multidisciplinary expertise lies in experimental strategies supporting high-throughput multivariate quantitative approaches, in which established and new technologies are integrated to characterize cell/viral vector products and their manufacturing processes. He was previously Lead Scientist at the Cell and Gene Therapy Catapult, Science Leader in Cell Metrology at LGC, the UK designated National Measurement Institute for chemical and bio-measurements. He started his industrial career as Senior Scientist at ReNeuron, where he characterized the company’s first clinical neural stem cell line for stroke therapy.
Managing Director, MMIC, Biologics & Quality
The Medicines Manufacturing Innovation Centre is a collaboration between CPI, University of Strathclyde, UK Research & Industry, Scottish Enterprise and founding industry partners, AstraZeneca and GSK.
The centre will ensure the UK is a technology and innovation leader in pharmaceutical manufacturing, thereby boosting the competitiveness of both sectors. The initial focus will be on technology translation for small molecule drug manufacture.
Dave also leads the Biologics business unit, CPI’s Quality function, which includes GMP obligations, and CPIs PMO function.
Prior to joining CPI in January 2019 Dave worked for GSK. He joined the company in 1992 as a PhD Chemist from Glasgow University. He has over 20 years’ experience at GSK carrying out a number of Technical, Compliance and Manufacturing leadership roles. In 1997 he moved to Irvine to take up a lead chemist role before coming Quality Control Manager in 1998. He joined the site leadership team in 2001 to run Technical Development before moving to manufacturing as Actives Production Director in 2005.
During this time he completed a Masters degree in Manufacturing Leadership at Cambridge University. In 2007 he moved to GSK House to work on a central network re-structuring project before becoming Site Director at Montrose in October 2008. At Montrose, he led the transformation of the site to manufacture over 12 products for GSK including a major investment programme. In 2011 he was appointed VP Primary Supply Chain with responsibility for global Active Pharmaceutical Ingredients (API) manufacture and supply, a network of GMS sites across the world including facilities in Asia and Europe. In 2017 he was appointed VP Head of GMS Strategy with responsibility for manufacturing strategy, deployment of strategic programmes, performance management and advocacy.
He plays an active role with a number of Governments and is currently co-chair of the Life Sciences Scotland Industry Leadership Group.